Tag Archives: Gavi

Accelerating Global Access to Vaccines in Developing Countries

26 Apr

 

Pfizer is dedicated to increasing access to immunizations in countries that carry the greatest proportion of global burden of pneumococcal disease, which can help prevent diseases and save lives.

In support of this commitment, and to help address the practical constraints experienced by health workers operating in many Gavi countries, Pfizer developed Prevenar 13® in the Multi-Dose Vial-MDV presentation (4 doses per vial). This new presentation will help to significantly reduce storage requirements and shipping costs in communities with health systems that are still developing. In April 2016, the MDV presentation received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Subsequently the MDV was pre-qualified by the WHO in July 2016.

In January 2017, Pfizer launched the new multi-dose vial- MDV which was prequalified in accordance with WHO’s ‘open container policy.’ With its ‘open container’ attributes, it allows for the fourth dose to be used for up to 28 days after the first dose in drawn and providing the recommended cold storage requirements have been met.

To ensure the efficient use of the multi-dose vial, Pfizer is supporting Gavi countries with a refresher training of trainers program on a variety of immunization topics including the proper handling of multi dose vials with open container policy. Pfizer partnered with AMP Services, an organization dedicated to providing the tools to promote preventive medicine and public health worldwide, to execute the training of trainers sessions in 16 countries in 2017. Continue reading

Advertisements
%d bloggers like this: